Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | enrolling by invitation | Phase 2 | 500 | Autolus LimitedINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06987058 | RVU120 Rollover Study(ROVER-01) | enrolling by invitation | Phase 2 | 14 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07813390 |
| Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML) |
| enrolling by invitation |
| Phase 2 |
| 73 |
| Guangdong Second Provincial General HospitalOTHER |
| 1 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | enrolling by invitation | Phase 2 | 332 | Taiho Oncology, Inc.INDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT07651163 | Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 450 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651176 | Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 267 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07537257 | VEN+IDAC vs IDAC in AML | enrolling by invitation | Phase 2 / Phase 3 | 232 | Guangdong Second Provincial General HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07517510 | HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).(HVA-MPAL) | enrolling by invitation | Phase 2 | 40 | Guangdong Second Provincial General HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03031249 | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | enrolling by invitation | Phase 1 / Phase 2 | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT02646839 | KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | enrolling by invitation | Phase 2 | 50 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04836390 | Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant(EXCEL) | enrolling by invitation | Phase 2 | 30 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06560879 | Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia | enrolling by invitation | Phase 2 | 120 | National Institute of Pediatrics, MexicoOTHER_GOV | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06544109 | Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients(Ven APL) | enrolling by invitation | Phase 2 / Phase 3 | 98 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials